At a glance
- Originator Pfizer
- Class Antihyperlipidaemics
- Mechanism of Action Microsomal triglyceride transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 23 May 2000 New profile
- 23 May 2000 Preclinical development for Hyperlipidaemia in USA (Unknown route)